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Hepatic failureCritically ill patients are at high risk for development of life-threatening infection leading to sepsis and multiple
organ failure. Adequate antimicrobial therapy is pivotal for optimizing the chances of survival. However, efﬁcient
dosing is problematic because pathophysiological changes associatedwith critical illness impact on pharmacoki-
netics of mainly hydrophilic antimicrobials. Concentrations of hydrophilic antimicrobials may be increased be-
cause of decreased renal clearance due to acute kidney injury. Alternatively, antimicrobial concentrations may
be decreased because of increased volume of distribution and augmented renal clearance provoked by systemic
inﬂammatory response syndrome, capillary leak, decreased protein binding and administration of intravenous
ﬂuids and inotropes. Often multiple conditions that may inﬂuence pharmacokinetics are present at the same
time thereby excessively complicating the prediction of adequate concentrations. In general, conditions leading
to underdosing are predominant. Yet, since prediction of serum concentrations remains difﬁcult, therapeutic
drug monitoring for individual ﬁne-tuning of antimicrobial therapy seems the way forward.
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Dose–response relationships are indispensible to determine the
therapeutic window of a drug and to deﬁne safe and deleterious
concentrations and dosages. In general, these studies are conducted
in healthy volunteers after which dosing is ﬁne-tuned in mild-to-
moderately ill patients. Results from these trials are frequently extrapo-
lated for the use in critically ill patients. Such extrapolations presume
comparable drug pharmacokinetics (PK) and pharmacodynamics (PD)
in critically ill patients compared to patients with rather mild illness.
Yet, critically ill patients may demonstrate multiple organ derange-
ments inciting pathophysiological changes that can affect PK/PD prop-
erties of drugs. These changes can occur within an individual patient
and may deviate according to the varying stages of illness. As such dos-
ages being adequate at a given day may become inadequate some days
later because of alterations in disease severity. In addition, critically ill
patients usually receive a wide range of drugs thereby adding to the
possibility of drug–drug interactions. Commonly prescribed drugs in in-
tensive care units (ICUs) include sedatives and analgesics, anticoagu-
lants, immunosuppressive and anticonvulsive agents, drugs with
cardiovascular activity, and antimicrobials.
Basically the general principles of PK include absorption, distribu-
tion, metabolism, and elimination. Critical illness affects all of these pro-
cesses thereby signiﬁcantly inﬂuencing the PK of drugs [1]. Absorption
refers to the process by which a drug leaves the site of administration
(either by the enteral route, inhalation, topical, subcutaneously, intra-
muscular, or rectal) and concentrates in the circulation thereby
representing the bioavailability. The amount of drug absorbed depends
on drug characteristics (physicochemical properties, particle size, solu-
bility, etc.) and properties of the organ/tissue of drug administration. For
example, regarding enterally administered drugs, shock will reduce re-
gional blood ﬂow and motility, resulting in delayed gastric emptying
and diminished absorption [2]. The use of vasopressors to restore arte-
rial blood pressure will not per se normalize regional perfusion as
these drugs have differing effects on organ vascular beds and notably
on splanchnic blood ﬂow. Alternatively, during shock or use of vaso-
pressors skin perfusion will be reduced thereby decreasing absorption
of subcutaneously administered drugs. Because of the issues of absorp-
tion intravenous drug administration is usually recommended during
critical illness [3].
Volume of distribution (Vd) describes the relationship between dose
and the resulting serum concentration. Critical illness and a plethora of
associated interventions affect the distribution of drugs. Sepsis, shock,
burn injury, pancreatitis, and alterations in plasma protein binding are
just a few examples of disease entities inﬂuencing Vd. Alternatively
ﬂuid resuscitation, as frequently necessary in critically ill patients will
also lead to increased Vd.
Drug metabolism occurs predominantly in the liver. The ability of
the liver to clear drugs is proportionate to blood ﬂow and/or the hepatic
extraction ratio of the drug, mainly driven by the cytochrome P450 en-
zyme system [1]. Critical illness affects metabolic activity by alterations
in plasma protein concentration, hepatic enzymatic activity and blood
ﬂow [4,5]. Additionally, many drugs used in critically ill patientsmay ei-
ther induce or inhibit the activity of the various isoenzymes included in
the cytochrome P450 complex.
Finally the elimination process can be disturbed during critical ill-
ness as renal clearance can be either enhanced or impaired. Augmented
renal clearance can be driven by sepsis, burn injury, or use of inotropic
agents [6]. On the other hand, acute kidney injury may complicate the
ICU course [7,8]. Acute kidney injury may represent partial or complete
loss of renal function. In the latter case renal replacement therapy will
be necessary.
In the rest of this article we particularly focus on alterations in PK
of antimicrobials in critically ill patients. In this regard antimicrobials
are of extreme interest because (i) their PK is particularly vulnerable
for the pathophysiological alteration during critical illness, (ii) dosingis not titrated to an immediately observed effect, and ﬁnally
(iii) underdosing is associated with insufﬁcient bacterial eradication
and as suchwith bad outcome,while overdosingmayprovoke addition-
al organ failure in a patient population already at increased risk
for organ derangements. As such, the objective of this review is to sum-
marize pathophysiological changes that may take place during critical
illness, and their effect on pharmacokinetics of antimicrobials.
2. Infection and sepsis in the critically ill
Critically ill patients are at an increased risk for severe infection be-
cause of the extensive use of invasive devices for diagnoses and therapy,
and because of their weakened physical condition [9]. Large point-
prevalence studies indicated that 40% to 50% of critically patients expe-
rience infection during their intensive care unit (ICU) course [10,11].
Serious infections, such as bacteremia or pneumonia, incite a sys-
temic inﬂammatory response syndrome (SIRS) indicating that the infec-
tious process goes beyond local inﬂammation and affects the total
organism. SIRS is part of the innate immune response and is, as per def-
inition, characterized by the presence of at least two of the following
conditions: fever or hypothermia, leukocytosis or leukopenia, tachycar-
dia, tachypnoea, and hypotension [12]. Infections provoking SIRS pro-
duce the syndrome called sepsis. According to the level of severity a
categorization is made between sepsis, severe sepsis and septic shock.
Severe sepsis is associated with organ failure, while septic shock is ac-
companied by hypotension refractory to adequate ﬂuid administration
and necessitating vasopressor support.
The mortality rate associated with sepsis is approximately 20% to
30%, while mortality in patients with severe sepsis is about 30% to 50%
[13,14]. An important proportion of this mortality rate is due to overall
severity of acute illness and underlying disease [15,16]. The broad
window of mortality can be explained by differences in source of infec-
tion [11], patients' age and underlying pathology (e.g. neutropenic pa-
tients) [17,18], microbial etiology and antimicrobial susceptibility
patterns [19,20], associated organ failures [14,21], and adequacy of anti-
microbial therapy. Prompt initiation of antimicrobial therapy limits the
attributablemortality [22], but nevertheless outcomes often remain un-
acceptably grim and it has been hypothesized that the optimization of
drug exposure might be the way forward in critically ill patients
[23–25].
3. Deﬁning adequate antimicrobial therapy
For antimicrobial therapy to be adequate, three requirements need
to be fulﬁlled. First, the antimicrobial agent(s) should be initiated as
soon as possible after the onset of sepsis [26,27]. In general this is before
the causative pathogen is known. Second, as therapy is to be initiated
empirically, the antimicrobial spectrum of the agent should be broad
enough to cover the potential causativemicroorganisms [28,29]. Finally,
appropriate antimicrobial dosing is required tomaximizemicrobial kill-
ing, minimize the development of multidrug antimicrobial resistance,
and avoid concentration-related adverse drug reactions [30–32].
While in the 1990s and the early 2000s therewas a clear emphasis in
the literature on the importance of empirically selecting the appropriate
antimicrobial agent; in the recent years more attention has been given
to the issue of adequate dosing. Inmild-to-moderately ill patients target
antimicrobial concentrations are achieved with standard dosages, as
pharmacokinetics are relatively stable and foreseeable. As alreadymen-
tioned however, in critically ill patients, PK is prone to a variety of path-
ophysiological alterations, thereby complicating optimal dosing.
4. Physicochemical properties of antimicrobial agents
The choice of appropriate antimicrobial dosing in critically ill pa-
tients is greatly affected by the intrinsic physicochemical properties of
the drugs [33]. As a general rule, clinicians must be aware of the fact
Fig. 1. Physicochemical properties of antimicrobials and dosage requirements in the presence of severe sepsis. *Need for dose reductions only indicated in case of severe hepatic failure.
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be affected by the presence of sepsis. This is in relation with the limited
tissue distributionof these agentswhich is normally restricted to the ex-
tracellular space, so that signiﬁcant antibiotic dilution might occur
whenever intravascular ﬂuid escape into tissues. Additionally, since al-
most all of these agents are normally cleared by the renal route, this
means that ﬂuctuations of renal function, which usually occur in septic
patients, may increase or decrease their elimination rates. Conversely,
lipophilic antimicrobials are less signiﬁcantly affected in their pharma-
cokinetic behavior by the pathophysiology of sepsis. This is because
they are normally distributed also within cells, and this means that
retrodiffusion from the intracellular reservoir to the extracellular
space may prevent antibiotic dilution whenever intravascular ﬂuid es-
cape into tissues. Additionally, most of these agents are cleared through
the liver, whose function is often less signiﬁcantly compromised during
sepsis, so that their elimination rates are frequently similar to those ob-
served in stable patients.
Accordingly, hydrophilic antimicrobials often need higher loading
dosages and increased or decreased maintenance dosages in critically
ill septic patients in comparison with non-critical stable patients. On
the contrary, similar concentration-time proﬁles are observed for lipo-
philic agents in critically ill as well as non-critically ill patients.
5. Pharmacokinetic and pharmacodynamic parameters of
antimicrobial agents
Dosage and length of the dosing interval must be determined by
considering the pharmacokinetic–pharmacodynamic relationships of
the antimicrobial agent. Pharmacokinetic (PK) parameters determine
the concentration-time course of the antimicrobial agent. The most im-
portant PK parameters include the area under the plasma concentration
time-curve (AUC0–24 h), the peak plasma concentration (Cmax), and the
trough concentration or the concentration prior to the next dose (Cmin).Pharmacodynamics refers to the relationship between the antimicrobial
concentration and the observed effect on the target pathogen. Crucial
hereby is the in vitro susceptibility of the involved microorganism
(minimal inhibitory concentration, MIC). According to the differences
in dose–response relationships, antimicrobials are broadly classiﬁed in
one or more of the following PK/PD categories (Table 1):
(i) Non-concentration dependent, more commonly known as time-
dependent: antimicrobial effect is deﬁned by the cumulative per-
centage of time over a 24 hour period that the free (or unbound)
antimicrobial concentration exceeds the MIC (f TNMIC). Beta-
lactam antimicrobials are examples of time-dependent agents.
Concentration far exceeding that of the MIC will not contribute
to better killing rates [34].
(ii) Concentration-dependent: antimicrobial effect is deﬁned by
the peak concentration in a dosing interval divided by the
MIC (Cmax / MIC). Aminoglycosides and daptomycin are
concentration-dependent agents. The usual target is a Cmax / MIC
that exceeds 8–10.
(iii) Concentration-dependent with time-dependence: antimicrobial
effect is deﬁned by the AUC0–24 h over a 24-hour period divided
by the MIC (AUC0–24 h / MIC). Examples are ﬂuoroquinolones,
tigecycline, linezolid and glycopeptides [35]. Speciﬁc targets vary
according to the antimicrobial.
6. Pathophysiological alterations in critically ill patients affecting
antimicrobial pharmacokinetics
As already mentioned during critical illness several pathophysiolog-
ical changes occur that may alter PK of drugs, mainly of the hydrophilic
ones. Oftenmultiple conditions thatmay inﬂuence PK are present at the
same time thereby excessively complicating the prediction of adequate
concentrations. Regarding antimicrobials, basically the ﬁve main issues
Table 1
Pharmacokinetic and pharmacodynamic properties of antimicrobial agents (after [39]).
Concentration-dependent Time-dependent Concentration-dependent with time-dependence
Objective Maximize concentrations Maximize duration of exposure Maximize amount of drug exposure
Optimal PK/PD index Cmax/MIC T N MIC AUC0–24 h / MIC
Antimicrobials Aminoglycosides Carbapenems Azithromycin
Daptomycin Cephalosporins Clindamycin
Fluoroquinolones Erythromycin Linezolid
Ketolides Linezolid Tetracyclines
Metronidazole Clarithromycin Fluoroquinolones
Quinupristin/dalfopristin Lincosamides Aminoglycosides
Penicillins Quinupristin/dalfopristin
Tigecycline
Vancomycin
6 S.I. Blot et al. / Advanced Drug Delivery Reviews 77 (2014) 3–11may cause alterations in PK: (1) increased Vd, (2) alterations in protein
binding, (3) augmented renal clearance, (4) impaired renal clearance,
and (5) hepatic dysfunction.
6.1. Increased volume of distribution (Vd)
Sepsis and particularly septic shock are characterized by vasodilata-
tion and increased vascular permeability leading to capillary leak syn-
drome [36]. This capillary leak is responsible for a ﬂuid shift from the
intravascular compartment to the interstitial space [37] leading to
edema formation. This third-spacing phenomenon is enhanced by
oncotic pressure caused by plasma proteins leaked through the capillary
leak [38]. The increased vascular capacity by vasodilatation on one hand
and the loss of intravascular volume on the other hand necessitate the
administration of intravenousﬂuids in order tomaintain sufﬁcient pres-
sure to perfuse organ beds. Edema formation and intravenous ﬂuid
administration contribute to a vast increase in total bodywater substan-
tially increasing Vd of hydrophilic antimicrobials. The clinical
importance of an increased Vd is particularly relevant for those antimi-
crobials (beta-lactams, aminoglycosides, glycopeptides, polymyxin B)
that normally have a rather low Vd. If initial loading dosages are not in-
creased, it might take one to two days before stable serum concentra-
tions are reached, thereby compromising clinical outcomes.
Indeed, Vd of hydrophilic antimicrobials is not only increased by
edema formation andﬂuid administration but also by several frequently
performed interventions might contribute to this, such as mechanical
ventilation, extra-corporal circuits (e.g. cardiopulmonary bypass or
plasma exchange), and post-surgical drainage [39]. As such, not only
sepsis or septic shock but also disease severity in general may cause
an increase in Vd. Speciﬁc pathologies leading to increased Vd include
advanced liver disease, mediastinitis, pleural effusion, and major burn
injury. Advanced liver cirrhosis may lead to an increase in extracellular
compartment ﬂuid and therefore Vd of hydrophilic antimicrobials
through ascites formation and plasma expansion [40,41]. Extravasation
of ﬂuid in the pleural cavity may also trigger Vd expansion resulting
in insufﬁcient concentrations of hydrophilic antimicrobials [42].
Mediastinitis can increase Vd of antimicrobials through sequestration
of plasma leading to a third spacing phenomenon [43]. Extensive
burn injury incites a strong inﬂammatory reaction and capillary leak
resulting inmassive oedema formation. Direct damage ofmicrovascular
integrity by the trauma itself further promotes extravasation of plasma
[44].
The relationship between increased Vd of antimicrobials and serum
concentrations has been the objective of many studies. For example, in
100 surgical ICU patients with Gram-negative sepsis, Vd and serum
concentrations of aminoglycosides were investigated [45]. Vd was in-
creased by 36% to 70% leading to the need for proportionally larger load-
ing dosages to achieve desirable target concentrations. The relationship
between Vd of amikacin and severity of acute illness as assessed by the
acute physiology and chronic health evaluation (APACHE) II scorewas in-
vestigated in 42 critically ill patients being treated for a Gram-negativesepsis [46]. Whereas the normal Vd of amikacin is about 0.25 L/kg and
the mean Vd measured was 0.41 L/kg (standard deviation 0.12 L/kg).
Vd correlated well with increased disease severity (r = 0.70; P b 0.001)
leading to the conclusion that in critically ill patients larger loading
doses of aminoglycosides are necessary to achieve target concentrations.
A PK study on intravenous polymyxin B in critically ill patients demon-
strated that PKwasmainly dependent on total bodyweight,which closely
related toVd [47]. AdditionalMonteCarlo simulations indicated that ther-
apeutic regimens might beneﬁt from a loading dose.
Conversely, nomajor inﬂuence onVd is expectedunder the aforemen-
tioned conditions for lipophilic antimicrobials. For example, no signiﬁcant
increase in Vd was observed for ciproﬂoxacin in patients with intra-
abdominal sepsis, suggesting that third-space losses and ﬂuid
resuscitation had no signiﬁcant inﬂuence for this lipophilic antimicrobial
[48].6.2. Protein binding
Protein binding is a relevant property of drugs as only the unbound
fraction is pharmacodynamically active and can achieve drug efﬁcacy or
cause toxicity. Hypoalbuminemia frequently occurs during critical ill-
ness. More than 40% of patients admitted to ICUs have a serum albumin
concentration of≤25 g/dL at baseline [49]. Protein binding is likely to be
clinically relevant when the antimicrobial agent is highly protein bound
(N85–90%) and predominantly cleared by glomerular ﬁltration, as it oc-
curs for some hydrophilic antimicrobials like ertapenem, daptomycin,
ceftriaxone and teicoplanin [50]. Lower serum protein concentrations
result in greater proportions of unbound drug and may therefore tem-
porarily result in high drug concentrations and optimal bacterial killing
rates. Yet, as hypoalbuminemia is usually associated with increased Vd
and drug clearance of highly protein bound hydrophilic antimicrobials,
the free fraction will soon after administration be diluted over the in-
creased total body water and more rapidly cleared. As such hypoalbu-
minemia may contribute to initial target concentrations but failure to
maintain sufﬁcient drug concentrations throughout the dosing interval
necessitating a shorter dosing interval [50]. Roberts et al. summarized
data from eight studies on antimicrobials in critically ill patients with
hypoalbuminemia [50]. In all studies clearance in ICU patients was in-
creased compared with healthy volunteers while in most studies the
Vd was substantially increased. Yet, important differences between an-
timicrobials should be considered. For ceftriaxone, for example, clear-
ance increased by 99% while an increment in Vd of 32% was observed
[51]. For ﬂucloxacillin, clearance and Vd increased 10% and 57% respec-
tively [52,53]. The highest increments were observed in ertapenem
with clearance and Vd raises of 462% and 624%, respectively [54]. In
summary, hypoalbuminemiamay result in a greater unbound drug pro-
portion, and this means that in severe hypoalbuminemic patients
higher than standard loading doses and maintenance doses may be
needed for optimal exposure with highly protein bound hydrophilic
antimicrobials.
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Augmented renal clearance (ARC) refers to enhanced excretion of
circulating metabolites, toxins, waste products, and drugs as compared
to baseline as consequence of glomerular hyperﬁltration [55]. Initially,
the proposed deﬁnition of ARC uses glomerular ﬁltration rate values
10% above the normal upper value, i.e. N160 mL/min/1.73 m2 in men
and N150 mL/min/1.73 m2 in women [6]. More recently the cut-off
was set at a glomerular ﬁltration rate N130 mL/1.73m2 as values
above this threshold were associated with sub-therapeutic trough con-
centrations of beta-alctams [56]. As many hydrophilic antimicrobials
are eliminated by glomerular ﬁltration, ARC is likely to be an important
PK covariate. Also, as antimicrobial clearance is generally proportionate
to creatinine clearance (CLcr) [6,56–58], patients at risk for subthera-
peutic concentrations following ARC are becoming more recognized.
There is a variety of clinical conditions leading to ARC including sep-
sis, trauma, particularly burn injury, pancreatitis, autoimmune disor-
ders, ischemia, and major surgery [12,59–61]. Often these conditions
also lead to increased Vd, thereby providing an additional factor poten-
tially contributing to insufﬁcient antimicrobial concentrations. Fig. 2 il-
lustrates how increased Vd and ARC both inﬂuence antimicrobial
serum concentrations of hydrophilic agents. Basically, the reason for
ARC can be reduced to the presence of SIRS, characterized by a reduction
in systemic vascular resistance and increased cardiac output and
concomitantly increased glomerular ﬁltration rate if the kidneys
are not damaged [62]. In experimental sepsis models, increments in
cardiac output correlated with increased renal blood ﬂow, while in
cardiosurgical patients cardiac output was associated with creatinine
clearance (CLcr) [63,64]. To counteract the vasodilation ﬂuids and even-
tually vasoactive agents are administered. Experimental data demon-
strated that administration of crystalloids can increase CLcr, and that
noradrenaline is capable in enhancing cardiac output, renal blood
ﬂow, and CLcr [65–67].
The way in which ARC affects antimicrobial PK/PD depends on the
basis of their bacterial kill characteristics. For time-dependent antimi-
crobials, such as beta-lactams, it is important tomaintain adequate plas-
ma concentrations throughout the dosing interval. Therefore, such
antimicrobials are extreme vulnerable for the effects of ARC. Continuous
infusion of time-dependent antimicrobials has been suggested to max-
imize the duration of time that bacteria are exposed to adequate antimi-
crobial concentrations [32], especially when in the presence of
multidrug resistant Gram-negative infections [68]. A recentmulticentreFig. 2. Schematic illustration of the inﬂuence of increased volume of distribution and aug
mented renal clearance on serum concentrations of hydrophilic antimicrobial agents. Red
line indicates antimicrobial serum concentration. The shaded zone indicates the target in
terval for the antimicrobial concentration.-
-trial demonstrated that continuous infusion of beta-lactam antibiotics
in patients with severe sepsis resulted in higher plasma concentrations
and some better surrogate clinical outcomes, compared with intermit-
tent bolus infusions [69].
Conversely, Cmax is barely affected by ARC, being mainly dependent
on the Vd of a given drug and not on its clearance. Therefore the clinical
relevance of ARC on conditioning adjustments of maintenance dosages
of concentration-dependent antimicrobials such as aminoglycosides is
rather limited as Cmax / MIC is the most important PD index. However,
it should not be overlooked that these drugs can beneﬁt from higher
loading doses in order to compensate the increased Vd.Using a standard
loading dose of 25 mg/kg amikacin in 74 patients with severe sepsis or
septic shock, serumpeak concentrations did not reach the target Cmax of
8 times the MIC for Enterobacteriaceae and Pseudomonas aeruginosa in
30% of study subjects [70].
For concentration-dependent antimicrobials with time-dependence
such as ﬂuoroquinolones or vancomycin, the AUC0–24h/MIC is the cen-
tral PK/PD index. The impact of ARC on PK of these antimicrobials may
be relevant for renally cleared antimicrobials considering that for
these agents AUC0–24 h is inversely related to renal clearance. Standard
dosages of ciproﬂoxacin rarely reached target concentrations in 70 crit-
ically ill patients [71]. Also for the vancomycin use in ICUpatients, insuf-
ﬁcient drug concentrations were frequently observed and linked with
poor clinical outcomes [72,73]. Therapeutic drug monitoring could be
used to guide drug dosing in these patients.
6.4. Reduced renal clearance
6.4.1. Acute kidney injury
Acute kidney injury (AKI) is a common complication in the ICU, par-
ticularly in the context of sepsis [74–76]. A wide range of factors can
trigger the development of AKI, in particular shock due to hemorrhagic,
septic or cardiogenic causes [7]. AKI is diagnosed on the basis of either
an acute increase in the serum or plasma creatinine concentration or
the presence of oligo-anuria.
As a large number of hydrophilic antimicrobials are renally eliminat-
ed, AKI has an important inﬂuence on antimicrobial PK. Because antimi-
crobial clearance corresponds with CLcr [6,56–58], the impact of AKI on
the antimicrobial concentrations depends on the extent that renal func-
tion is impaired. Inmild-to-moderately ill patients dose adjustments for
renally cleared antimicrobials might be necessary for CLcr values below
50 mL/min although the need of this will vary according to the tolera-
bility and to the safety of the antimicrobial agent.
Indeed, the type of dosage adjustments should be different for
antimicrobials according to concentration-dependency or time-
dependency. As a general rule, for concentration-dependent agents,
like aminoglycosides and daptomycin, it is better to prolong the dosing
interval while maintaining unmodiﬁed the dose amount in order to
maximize Cmax/MIC ratio. Conversely, for time-dependent agents, like
beta-lactam, it is better to reduce the dose amount while maintaining
unmodiﬁed the dosing interval in order to maximize t NMIC.
The impact of altered PK in case of AKI depends also on the propor-
tion of the antimicrobial that is renally eliminated. Aminoglycosides are
nearly 100% cleared by glomerular ﬁltration. In the case of a certain re-
duction in CLcr, there will be proportionate reduction in aminoglycoside
clearance requiring a prolongation of the dosing interval [77]. Vancomy-
cin is a glycopeptide with large Vd and clearance that correlates with
CLcr [6]. Factors associated with adequate early vancomycin concentra-
tions were retrospectively investigated in 227 ICU patients [78]. A de-
creased CLcr was found to be an independent predictor of adequate
early vancomycin trough concentrations (N15 mg/mL) (OR per mg/mL
increase 7.1, 95% CI 2.0–25.0; p = 0.002). These data insinuate that re-
duced renal functionmay partially compensate for conditions in the crit-
ically ill patient that provoke suboptimal antimicrobial concentrations.
The need for dose adjustment will depend on gravity of renal dysfunc-
tion, degree of factors increasing Vd, whether a loading dose was
8 S.I. Blot et al. / Advanced Drug Delivery Reviews 77 (2014) 3–11given, duration of therapy, and target concentration. As TDM is standard
to guide vancomycin dosing, any sub- or supratherapeutic concentra-
tions can be adjusted.
More factors than just AKI might contribute to alterations in PK
observed in these patients. A careful approach to antimicrobial dose
adjustment in patients with AKI is required to guarantee that
predetermined PK/PD targets are still achieved to optimize clinical out-
comes. The overall clinical picture should always be taken into account.
As previouslymentioned, in critically ill patients Vd is often enlarged for
hydrophilic antimicrobials that distribute largely in extracellular water
(aminoglycosides, beta-lactams, glycopeptides, colistin) and this
means that they will demonstrate reduced serum concentrations
when using standard loading doses. Additionally, some antimicrobial
agents may present multiple elimination pathways that may compen-
sate the decreased renal clearance in the presence of AKI, so that
standard reductions of maintenance doses as recommended may po-
tentially result in substantial underdosing in critically ill patients. For
example, Pea et al. found that 400 mg of ciproﬂoxacin twice daily did
not result in antimicrobial accumulation in critically ill patients with re-
duced renal function, since the drug was compensatorily eliminated by
transintestinal secretion and by the hepatic pathway, and concluded
that in most cases dose reductions are not necessary [79]. Likewise, in
another study only 71% of renally adjusted start doses of piperacillin–
tazobactam in critically ill patients with AKI achieved target concentra-
tions [80]. Similar observations were made for cephalosporins [80] and
tigecycline [81]. These results highlight the need of considering the im-
portance of the compensatory role that multiple elimination pathways
may have for some antimicrobials in critically ill patients with AKI and
support the need for administering a higher loading dose to be given
in the initial 24 h of treatment even in this setting [82].
6.4.2. Renal replacement therapy
In the case of life-threatening AKI, renal replacement therapy (RRT)
may be required. Three types of RRT are frequently performed in
ICU patients: continuous, intermittent, or an in-between approach
(SLED). Continuous RRT can be applied as continuous venovenous
hemoﬁltration (CVVH), continuous venovenous hemodialysis (CVVHD),
and continuous venovenous hemodiaﬁltration (CVVHDF). All of these ap-
proaches are very efﬁcient in removing hydrophilic antimicrobials, in
particular thosewith lowprotein binding properties andhigh renal clear-
ance [83,84]. RRT complicates predictions of antimicrobial concentrations
as drug clearancemay vary according to themode of RRT, the dose of RRT
delivered, ﬁlter material and surface area, and blood ﬂow [83–86]. As
such, factors that may lead to underdosing as well as overdosing are to
be considered.With thedata available in literature nodeﬁnitive guideline
for antimicrobial dosing can be proposed as study results demonstrate
high interpatient variability. A useful attempt to stratiﬁed dosages of
antimicrobials during CRRT according to critical factors has been made
[25,84]. However, therapeutic drug monitoring seems to be the way for-
ward to optimize antimicrobial dosing in critically ill patients requiring
RRT [87].
6.5. Hepatic dysfunction
Hepatic dysfunction is caused by infection-associated with
cholestasis or hepatocellular injury, ischaemic hepatitis (shock liver
through hypoperfusion), hemolysis, or direct damage from hepatotoxic
pharmaceuticals [31,88,89]. Hepatic dysfunction is reﬂected by elevated
liver enzymes, bilirubin, and ammonia, or reduced synthesis of
coagulant factors [31]. Hepatic impairment may sometimes lead to ac-
cumulation of hepatically metabolized antimicrobials through reduced
clearance. However, liver diseases may be associated with variable
and non-uniform reductions in drug-metabolizing activities. In general,
the activity of the various CYP450 enzymes may be differentially affect-
ed in patients with cirrhosis, and glucuronidation is often affected to a
lesser extent than CYP450-mediated reactions.[90]. The Child–Pugh score is frequently used to guide dosage adjust-
ment in clinical practice, despite not being validated in critically ill pa-
tients. Of note, the only antimicrobials for which dosage reduction is
recommended for patients with Child–Pugh class C are metronidazole,
tigecycline, and caspofungin [91–94].
Alternatively, liver failure is associated with reduced production of
albumin leading to hypoproteinemia affecting Vd and protein binding.
Hepatic metabolization of antibiotics such as ﬂuoroquinolones and
ﬂucloxacillin is hampered by liver failure. Yet, it takes a reduction of at
least 90% of the metabolic capacity of the liver to substantially affect
drug clearance [95]. Besides intrinsic hepatic clearance, hepatic drug
clearance is also inﬂuenced by hepatic blood ﬂow. Changes in hepatic
blood ﬂow can affect drug metabolism by alterations in drug delivery
to the hepatocyte. This is particularly relevant for drugs with a high ex-
traction ratio (N0.7) [90]. Hepatic blood ﬂowmight be increased due to
the hyperdynamic status that characterizes sepsis and critical illness. It
is, however, unclear to which extent an increased hepatic blood ﬂow
may compensate for reduced hepatic enzyme activity due to liver
disease.
For drugs such as ciproﬂoxacin, which are eliminated renally as well
as by hepatic clearance, special attention should be given to patients in
whomhepatic dysfunction occurs in the presence of acute kidney injury
[31,79]. Because the impact of hepatic dysfunction on antimicrobial
elimination is difﬁcult to assess it is recommended to prescribe non-
hepatically eliminated agents. This might be particularly important
when accumulation of the antimicrobial might lead to hepatic toxicity,
further endangering the hepatic function.
7. Variability in target attainment of antimicrobial agents and
practical approach
A spectrumof pathophysiological changes and/or interventions pro-
vokes conditions that may result in either increased or decreased drug
concentrations. Fig. 3 summarizes the main conditions contributing to
this complex of circumstances making prediction of PK problematic.
Factors that contribute to increased antimicrobial concentrations in-
clude decreased hepatic and renal failure, and regional blood ﬂow albeit
that the latter is generally a temporarily event due to shock. Factors
leading to increased Vd and ARC of hydrophilic antimicrobials by
which concentrations tend to decrease include inﬂammation, edema
formation, post-surgical drainage, extra-corporal circulations, and the
administrations of ﬂuids and inotropic agents. Alteration in protein
binding has two consequences. Hypoalbuminemia resulting from liver
failure (e.g., cirrhosis) may lead to a greater free drug fraction and tem-
porarily higher exposure. However, cirrhotic patients often experience
ascites adding to an increase in Vd of hydrophilic antimicrobials. Also,
and more frequent in critically ill patients, hypoalbuminemia might re-
sult from capillary leak syndrome. Serum proteins leaked into the inter-
stitial space enhance edema formation and as such Vd.
One ormore of these factorsmay be present in various degrees of se-
riousness according to the severity of acute illness that – on its turn –
may vary in time (i.e. on a daily or even an hourly basis). As a conse-
quence intra- and inter-patient variability of target attainment in
critically ill patients is substantial and clinically relevant as has been
demonstrated with beta-lactams and vancomycin [80,96]. While evalu-
ating target attainments of antimicrobials one should consider the
threshold chosen. In a recent multinational PK point-prevalence study
concentrations of beta-lactams were evaluated with as main PK/PD tar-
get free concentrations above the MIC of the pathogen at both 50% and
100% of the dosing interval [97]. The study revealed that 21% of patients
did not achieve the minimum conservative PK/PD target of N50% T
N MIC. In order to achieve adequate bacterial killing, concentrations
should exceed 4 × MIC for 50% of the dosing interval; a target that
was only achieved by 49% of patients. The optimal scenario inwhich an-
timicrobial concentrations exceeded 4 × MIC for the total duration of
the dosing interval was observed in only 35% of the ICU patients.
Fig. 3. Review of pathophysiological alterations during critical illness and their potential effect on pharmacokinetics of antimicrobial agents. SIRS, systemic inﬂammatory response
syndrome; Vd, volume of distribution.
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tailored approach by means of TDM has been proposed. Historically,
TDM has been used for antimicrobials with a rather narrow therapeutic
window and a substantial risk of toxicity (e.g. aminoglycosides, vanco-
mycin), while it was considered less useful for agents with a broad ther-
apeutic index such as beta-lactams [98]. At least theoretically TDM
offers a way to counter the high inter-patient PK variability. The ratio-
nale for this is that TDM of antimicrobials may allow targeting drug ex-
posure in all of the patients, irrespective of their underlying conditions,
to the same value which is expectedwith the standard licensed dosages
in the healthy volunteers. This may maximize the likelihood of clinical
response and minimize that of adverse events. Yet, despite the success-
fully implementation of a beta-lactam TDM-program in ICU patients
[87], several issues remain. First, clinical advantage remains unproven.
Second, the technical requirements and expertise are not widely avail-
able. Third, the possibility of TDM does not solve the question of the
most optimal PK/PD target. Fourth, when the predeﬁned target is
missed it remains unclear how to titrate the dose. Finally, turnaround
times of TDM must be reduced. In the proof-of-concept paper by
Roberts et al. beta-lactam concentrations were available within 12 h of
sampling [87]. This may be advanced from a laboratory perspective
but it is probably too long from the clinical viewpoint, especially in
ﬁrst 48 h inwhich prompt and adequate antimicrobial therapy is crucial
to optimize the odds of survival [9,22]. Due to the high turn-around
time, TDM may well run behind the clinical scenario. Because the ﬁrst
two days represent a critical time in anti-infective management it is of
utmost importance to achieve target concentrations in a timelymanner.
It can be questioned if TDM is the best approach to achieve PK targets atearliest convenience. To increase the likelihood of early target attain-
ment, PK models can be developed to steer antimicrobial dosing in the
initial phase of therapy. These models can take into account status of
mechanical ventilation, diagnostic category, and glomerular ﬁltration
[99–101]. However, also here problems arise. Renal function is pivotal
in such models and often estimated by either Cockroft–Gault or modi-
ﬁed diet in renal disease formula. These formulas are based on single
serum creatinine concentrations and only validated in patientswith sta-
ble renal function. In the context of critical illness and acute kidney inju-
ry however, it might take hours or days for creatinine concentrations to
reach steady state. Moreover, other factors affecting PK such as the in-
ﬂuence of capillary leak on Vd (e.g. in septic shock or burn trauma)
are much more difﬁcult to estimate thereby hampering the develop-
ment of PK models that are valid for all expressions of critical illness.
8. Conclusion
Dosing of antimicrobials during sepsis or critical illness in general is
problematic as antimicrobial concentrations are subject to alterations.
Overall, the risk of suboptimal concentrations is higher than the risk of
adverse effects due to overdosing, especially for hydrophilic com-
pounds. Patients are at risk for overdosing in the case of fulminant
liver failure or strongly impaired renal function not covered by renal re-
placement therapy. But when starting antimicrobial therapy even in the
event of pending toxicity due to inefﬁcient clearance, the deleterious ef-
fects of overexposingwill be blunted by conditions generating a dilution
of the drug (increased Vd). From the available data in critically ill pa-
tients it is clear that underdosing is much more frequent than
10 S.I. Blot et al. / Advanced Drug Delivery Reviews 77 (2014) 3–11overdosing. Inadequate drug concentrations are clinically relevant as
they lead to inefﬁcient microbial killing and hence, compromise clinical
outcomes. In addition, suboptimal antimicrobial concentrations further
trigger the development of multidrug resistance, which on its turn fur-
ther complicates antimicrobial therapy through reduced odds of empir-
ic appropriate treatment. This suggests antibiotic TDM will become
more commonly used to assist optimal dosing within the ICU.References
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